<DOC>
	<DOCNO>NCT03038594</DOCNO>
	<brief_summary>The investigator previously demonstrate thermal injury cause severe muscle wasting , weight height retardation , systemic protein catabolism pediatric adult burn patient . The persistent loss muscle impair quality life burn patient , also delay autonomy reintegration community . In 2009 , investigator show daily injection recombinant human growth hormone ( GH ) nine month post discharge significantly increase height weight , well lean body mass , pediatric burn subject . Our long-term goal improve quality life burn patient prevent height , weight , muscle loss may occur severe protein catabolism . The objective application ) attenuate height weight burn patient administration GH , b ) prevent reverse loss muscle strength patient , c ) collect pilot data cardiopulmonary parameter , scar assessment , muscle metabolism . Our central hypothesis administration GH restore deplete level growth hormone lead prevention lean body mass loss bone mineral content , improve rehabilitation , accelerate reintegration severely burn patient . The investigator administer either placebo GH ( daily subcutaneous injection 0.05 mg/kg/day GH [ somatropin , Genotropin , Pfizer , New York , NY ] adult burn subject ( n=31 per group , 18-85 year , &gt; 30 % total body surface burn ) nine month begin one week prior discharge . Both group study total two year . The follow aim test : 1 ) determine effect GH supplementation body composition , lean body mass loss , muscle strength , exercise endurance ; 2 ) ass whether rehabilitation subsequent reintegration severely burn patient society accelerate . Investigators measure change lean body mass , muscle strength exercise endurance acute hospital stay , discharge , long-term follow-up visit ( 6 , 12 , 18 , 24 month discharge ) , well secondary endpoint cardiopulmonary variable ( rest energy expenditure , rest heart rate , cardiac output , stroke volume , liver size ) , hypertrophic scar development , muscle protein synthesis breakdown rate , concentration relevant hormone , cytokine , oxidative stress marker . The propose research innovative administration growth hormone adult burn patient explore .</brief_summary>
	<brief_title>Growth Hormone Therapy Muscle Regeneration Severely Burned Patients</brief_title>
	<detailed_description>Either recombinant human growth hormone ( daily subcutaneous injection 0.05 mg/kg/day GH discharge [ somatropin , Genotropin , Pfizer , New York , NY ] ; 0.025 mg/kg/day GH titrate week discharge ) placebo ( n=31 ) administer adult burn subject ( n= 31 , 18-85 year ) screen voluntary consent â‰¥30 % TBSA assess either Lund Browder chart 'rule nine ' method excisional surgery . It administer daily 9 month begin week discharge , primary secondary endpoint collect acute hospital stay , discharge , long-term follow-up visit ( 6 , 12 , 18 , 24 month discharge ) . Additionally , subject contact frequently [ likely 1 week , 1 month , 2 month post discharge telephone ] ensure adverse event concern study drug , well visit clinical visit address post-burn need . All subject receive similar standard medical care treatment time emergency admission discharge . Growth hormone use potentially attenuate loss height , weight , muscle bone , reverse oxidative stress burn injury , process , decrease secondary consequence burn injury , include organ dysfunction . This may improve quality life burn patient prevent pathophysiology may result muscle bone loss may reduce hospital stay . Our research lay foundation future development effective , safe , economic therapeutic intervention treat burn injury-associated metabolic abnormality . Also , provide basis development supplemental regulation pharmacotherapy treat burn patient GH . The risk reasonable relation anticipate benefit subject ) GH high dose test pediatric burn subject minor adverse event , b ) subject monitor consistently .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>INCLUSION CRITERIA 1885 year old Over 30 % total body surface area burn EXCLUSION CRITERIA History AIDS , AIDSrelated complex , HIV History hepatitis Pregnancy History Active Malignancy History Insulin Dependent Diabetes Mellitus Type I II Other hyperglycemic disorder [ include transient postburn/trauma hyperglycemia ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Burns</keyword>
	<keyword>Growth Hormone</keyword>
	<keyword>Lean Body Mass</keyword>
	<keyword>Strength</keyword>
	<keyword>Exercise Endurance</keyword>
</DOC>